Skip to main content
Coherus BioSciences, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.100
+0.279 (33.90%)
At close: Nov 20, 2024, 4:00 PM
0.971
-0.129 (-11.75%)
Pre-market: Nov 21, 2024, 5:49 AM EST

Coherus BioSciences Revenue

Coherus BioSciences had revenue of $70.77M in the quarter ending September 30, 2024, a decrease of -5.09%. This brings the company's revenue in the last twelve months to $304.34M, up 44.19% year-over-year. In the year 2023, Coherus BioSciences had annual revenue of $257.24M with 21.89% growth.

Revenue (ttm)
$304.34M
Revenue Growth
+44.19%
P/S Ratio
0.41
Revenue / Employee
$994,575
Employees
306
Market Cap
126.73M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023257.24M46.20M21.89%
Dec 31, 2022211.04M-115.51M-35.37%
Dec 31, 2021326.55M-149.27M-31.37%
Dec 31, 2020475.82M119.75M33.63%
Dec 31, 2019356.07M--
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Dec 31, 2014 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Compugen 59.85M
Fennec Pharmaceuticals 49.35M
Protalix BioTherapeutics 45.67M
TriSalus Life Sciences 26.89M
Zomedica 26.73M
Adverum Biotechnologies 1.00M
Zentek 29.13K
Revenue Rankings

CHRS News

More News